In December 2019, the Norwegian Institute of Public Health (NIPH) released a health technology assessment report regarding the effectiveness of uterine fibroids treatment. This assessment was initially commissioned to NIPH by the Centre for joint decision-making (Samvalgssenteret), which provides patients with relevant and reliable information about a diagnosis and available treatment options. The main objective of the report was to summarize key findings from systematic reviews about the comparative effectiveness of relevant treatment options for women with fibroids in the uterus. The appropriate treatment options are pharmacological treatment, embolization, myomectomy, and hysterectomy. The treatment options had to be compared to each other or no treatment (placebo).
The following results were obtained by NIPH:
- Hysteroscopic myomectomy probably increases the chance of getting pregnant compared to the absence of the treatment, but this result is uncertain due to wide confidence intervals
- Tranexamacid probably reduces bleeding in comparison to placebo
- Embolization probably reduces the time that is needed to get back to the activity in comparison to myomectomy and hysterectomy
- Selective progesterone receptor modulators possibly reduce symptoms in comparison to placebo
- Non-steroidal anti-inflammatory drugs probably reduce bleeding in comparison to placebo
- No evidence for the determination of the effectiveness of danazol or progestogens is available.
See the full health technology assessment report in Norwegian here.
On our website, you can order a ready-made report on reimbursement situation for hysterectomy in benign and malignant diseases of uterus. The report includes the reimbursement situation of:
- subtotal hysterectomy;
- total hysterectomy;
- radical hysterectomy.
Click here to see details.
Subscribe to our newsletter delivered every second week not to miss important reimbursement information.